624 Results
Sort By:
Published on April 19, 2023
Researchers have developed a personalized mRNA-based vaccine, mRNA-4157, that significantly delays disease recurrence in patients with resected high-risk melanoma when added to standard-of-care adjuvant pembrolizumab therapy. “For the first time in a randomized study with a control arm, the addition of an mRNA neoantigen vaccine appeared to augment the benefit…
Published on April 12, 2023
Responses to the immunotherapy PD-1 checkpoint blockade in patients with advanced melanoma was tied to whether they had received a previous immunotherapy, CTLA-4 blockade, as well as other factors according to research published this week in Cancer Cell. The findings, by researchers at UCLA Jonsson Comprehensive Cancer Center, was based…
Published on April 12, 2023
Easily accessible information from hematoxylin and eosin (H&E)-stained tumor tissue on microscopy slides can predict which patients with metastatic clear cell renal cell carcinoma (mccRCC) are most likely to respond to immunotherapy, with the prediction further refined by adding PBRM1 mutation status, research suggests. The findings, from a retrospective study…
Published on April 12, 2023
Researchers at Northwestern University have developed a fast and non-invasive method to isolate tumor-reactive lymphocytes from peripheral blood instead of tumor tissue, potentially improving tumor-infiltrating lymphocyte therapy for cancers that are difficult to reach. Tumor-infiltrating lymphocyte (TIL) therapy is a type of immunotherapy where naturally occurring T cells that have…
Published on April 7, 2023
University of Pittsburgh researchers have detailed how probiotic bacteria travel from the gut to cancer tumors and then stimulate immune cells to make melanoma immunotherapy more effective. The team showed that Lactobacillu reuteri, a lactic acid bacterium and known probiotic, stimulates cancer-killing T cells to secrete the compound idole-3-aldehyde (I3A).…
Published on April 4, 2023
Originally Aired: April 6, 2023Time: 11:00 am PT, 2:00 pm ET, 20:00 CET VIEW NOW Immune checkpoint inhibition with monoclonal antibodies targeting PD-1 and PD-L1 has revolutionized the care of patients with advanced cancer, with approvals in multiple solid tumor types and pan-tumor indications. However, current pan-tumor biomarkers do not identify most patients…
Published on March 1, 2023
New research shows that using a chemical blocker stops CD8+ T cells from migrating out of skin cancer cells. Together with immunotherapy, the combination stopped melanoma tumor growth in half of treated mice, representing a potential new approach for boosting the efficacy of immunotherapy. In a paper in Nature Immunology,…
Published on February 22, 2023
CD5+ cells could be an important marker for response to immunotherapy, according to new research from the Washington University School of Medicine. In lab studies, this team found that patients whose tumor samples had more CD5+ dendritic cells lived longer. Also, mice without CD5 on their dendritic cells did not…
Published on February 8, 2023
Researchers at the Massachusetts Institute of Technology (MIT) has found in a mouse study that bacteria naturally found in the lungs help create an environment that suppresses T-cell activation in the lymph nodes near the lungs—a finding that could explain why immunotherapy for lung cancer often fails. The same immune-supressive environment…
Published on January 26, 2023
Tumor mutation burden (TMB) has become a biomarker used to predict patient response to specific immunotherapies. Now, new evidence from researchers at the Johns Hopkins Kimmel Cancer Center have found that a subset of mutations within the TMB—defined at “persistent mutations”—are less likely than others to be edited out, making…
Published on January 25, 2023
A team of researchers from Moffitt Cancer Center have shown a novel approach to increase the numbers of tumor-infiltrating lymphocytes (TILs) and their antitumor activity. In research published in Nature Cancer, the investigators demonstrate, in mouse models, how L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown…
Published on January 11, 2023
Researchers in China have shown that using immune checkpoint inhibitors prior to surgery of patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) is an effective approach to treating the disease, as opposed to surgery followed by neoadjuvant therapy. The findings, published in JNCCN—Journal of the National…
Published on December 28, 2022
Gilead Sciences and Jounce Therapeutics announced late Tuesday amendments to the existing terms and licensing agreements for GS-1811 (previously called JTX-1811), a potential first-in-class anti-CCR8 antibody in development as a potential treatment against solid tumors. The new deal will see the termination of certain operational obligations and Gilead will buy…
Published on December 21, 2022
Scientists at the University of Pittsburgh have discovered that tired T cells not only lose their own ability to fight cancer; they also influence surrounding cells to suppress an immune response. And they learned that one of the drivers of exhausted T cells is an environment low in oxygen. In…
Published on December 14, 2022
Clinical-stage biopharma Qu Biologics has announced a collaboration with Sweden’s Karolinska Institute (KI) to characterize the molecular targets of Qu’s Site Specific Immunomodulators (SSIs), an immunotherapy platform designed to restore innate immune function. The research will be led by Prof. Jonas Fuxe, who will become the head of laboratory medicine…